Linus Pauling Biotech Symposium - Symposium Speakers

Mr. Stéphane Hogan MSc, MBA. Head of Coordination Unit, Directorate Health, DG Research, European Commission.

Stéphane Hogan is currently Head of the Coordination Unit in the Health Directorate of DG Research. His unit is responsible for planning and coordination of the Health research programme in the EC's 7th Framework programme, which foresees €6.1 billion in grants for Health research over the period 2007-2013. His unit also addresses cross-cutting issues such as industry participation, international cooperation, ethics and communication. Prior to that he spent several years in research in Ireland and Belgium, then worked in journalism and in corporate communications in France, before joining the European Commission (DG Research) in Brussels in 1996. Stéphane holds a degree in science (Genetics) and an MSc in Biotechnology from Trinity College Dublin (Ireland), as well as an MBA from The Open University (UK).

Dr. Roger Bossé Sales Development Leader BioDiscovery, PerkinElmer, Canada

Roger Bossé holds a Ph.D. in Pharmacology from the University of Sherbrooke (Quebec, Canada). He completed his Post Doctoral training in Neuroendocrinology in Marc Caron’s lab (Cell Biology, Duke University, NC). Dr. Bossé joined BioSignal in 1996 as the R&D Group Leader responsible for the development of the GPCR pipeline. Following the acquisition of BioSignal by Packard in 1998, he was promoted Associated Director R&D and his team developed the AlphaScreen product line. After the merger between PerkinElmer and Packard BioSciences in 2001, Dr. Bossé and his team initiated the development of the AlphaLISA platform. In 2006, he transitioned to new functions in Business and Sales development. Dr. Bossé co-organized the 13th SBS annual meeting in Montreal in 2007. He was elected on the SBS board of directors in 2008. He also created a new Special Interest Group (SIG) on Drug repositioning within SBS.

Troy A. Groetken Shareholder, McAndrews, Held & Malloy, Ltd.

Troy is also a consultant clinical pharmacist registered and licensed in Illinois, Iowa and Michigan. As a registered patent practitioner, Troy regularly counsels international and Fortune 100 and 500 clients regarding advanced patent prosecution, licensing, complex transactional issues, due diligence analysis, competitive landscape preparation and utilization, white space analysis, opinion development, patent litigation, and global portfolio management matters involving chemical, pharmaceutical and biotechnological technological disciplines ranging from new drug (small-molecule, recombinant, combinational technologies, etc.) entities, surfactant technologies, agricultural compositions, food technologies, gellants, polyols, lubricants, coatings, laundry and cleaning products, pharmaceutical supplements, personal care and cosmetic formulations, alternative fuels, and renewable energies. Prior to practicing patent law, Troy has worked as a clinical consultant pharmacist, supervised drug research programs, evaluated drug management protocols, and performed drug treatment trials on behalf of the FDA. Troy is a member of the Illinois and Iowa State Bar Associations, member of the Federal Circuit Bar Association, American Chemical Society, American Pharmaceutical Association, and Intellectual Property Law Association of Chicago. Troy is also the past-President and current Board Member to the Association of Patent Law Firms. Troy has presented regularly, domestically and internationally, on a variety of intellectual topics at organizations, corporate entities, and law schools. Troy was recently selected as a “Rising Star” by the Illinois Super Lawyers independent survey for 2008 and 2009. He was also recently selected by his peers as one of 40 Illinois Attorneys Under Forty to Watch, which is an independent selection process conducted by Law Bulletin Publishing Company, in which there were over 7,000 applicants, 700 nominees extensively patent law peer/client reviewed, and only 40 selected in 2009.

Dr. Rashmi H. Barbhaiya PhD. CEO, Managing Director and co-founder Advinus Therapeutics, India

Rashmi H. Barbhaiya is a Pharmaceutical Executive with 27 years of experience in Pharmaceutical R&D. He has a unique blend of management experience in Drug Discovery and Development, Novel Drug Delivery, Herbal and Generic products. He is one of the founders, CEO and Managing Director of Advinus Therapeutics, a research-based pharma company located in Bangalore and Poona, India. Dr. Barbhaiya started his industrial pharmaceutical career in 1980 with Bristol-Myers Company in the United States where he spent next 21 years. The diversity of his background and experience has played a key role in speedy and successful development of a number of drugs for the treatment of a variety of diseases such as, AIDS and other infectious diseases, cancer, depression, anxiety, hypertension, CHF, diabetes and mild to moderate pain, including migraine. In the capacity of Vice President in the Pharmaceutical Research Institute of Bristol-Myers Squibb, he also played a key role, working with the drug discovery organization, in introducing “developability” as a key criterion in lead optimization, selection of drug candidates for development and to reduce timelines for discovery to development transition as well as for IND filings. In the year 2002, he returned to India to join Ranbaxy as the President of R & D and led a team of over 900 professionals involved in generic, drug delivery, herbal and innovation-driven new drug research and development activities. He is also credited for attracting world-class experienced scientists from overseas and for enhancing an innovation-driven culture to create one of the leading pharmaceutical R & D organizations in India. He was instrumental in creating an R & D alliance between Ranbaxy and GSK, the first of its kind for an Indian company. He is also credited for creating an alliance between Medicine for Malaria Venture (MMV) and Ranbaxy for developing a novel antimalarial which is currently undergoing Phase III clinical trials. He obtained the Ph.D. degree in Clinical Pharmacology from the St. Bartholomew’s Hospital Medical College, University of London. He continued his education through post-doctoral training at the University of Florida and University of Wisconsin. His scientific contributions have resulted in over 150 publications. He has helped to organize a number of scientific symposiums around the world. He is a member of several professional societies, among them are AAPS, ASCPT and ISSX. He has served on the Editorial Boards of Antimicrobial Agents and Chemotherapy and Biopharmaceutics and Drug Disposition journals. Dr. Barbhaiya has received a number of awards for his scientific contributions. Some of these include AAPS Fellow, AAPS Meritorious Manuscript Award, AAiPS Outstanding Achievement Award, Ranbaxy Award for Excellence in Pharmaceutical Research and India Life Sciences Person of the Year 2007 by Burrill & Company.

Dr. Allan Riting Liu MD, PhD, MBA. Vice President, Wanbang Biopharmaceutical Group, Director of Business Development, Fosun Pharma Groupis

Allan Riting Liu in charge of the business or new development of Fosun Pharma and Wanbang Biopharma (subsidiary of Fosun), developing R&D strategies, and exploring global opportunities via in-licensing or equity investment. After his postdoc at University of Delaware, he worked as a Scientist at Eli Lilly (U.S. Headquarter) to develop osteoporosis and caner drugs. He also had two years as a business analyst at Purdue Technology Transfer Lab and three-years as a sales manager at Xian-Janssen, a J&J. He received an MBA at Purdue University (Krannert), a Ph.D. in biochemistry at University of Texas /M.D. Anderson Cancer Center at Houston, and an M.D. from Guangzhou Medical College Dr. Liu has made many business achievements including two technology transfers to Alpharma (U.S.), creation of the BD Department of Fosun Pharma Group, establishment of a joint-venture company with Anesiva (U.S.) for manufacturing needle-free lidocaine injection for the global market, and setting up a new drug R&D company with some U.S. scientists，a licensing and co-development deal for a FDA phase III blockbuster product from Israel, and two licensing deals for two marketed antidiabetic products from India. Dr. Liu was also an internationally recognized scientist in bio-lipid signals, the first in the world to discover that psychosine can mobilize intracellular calcium. In 2003, he received an honor/award as Guidant Scholar offered by Guidant Foundation (U.S.). In 2008, he received an honor as One-Million-Yuan-Subsidized Top Talent offered by Jiangsu Government (China).

Dr. Ying Luo Chairman and CEO Shanghai Genomics Inc, GNI Ltd, China

罗楹博士1982年考入中国协和医科大学，并于1986年前往美国康涅狄格州大学攻读生物医学博士学位。他于1992年进入美国加利福尼亚州大学旧金山分校做博士后，研究HIV的分子调控机理。随后从1993年到2000年在多家美国硅谷的生物技术公司工作，包括Aviron公司、Clontech公司、和Rigel公司。历任研究员、资深研究员、部门经理、资深部门经理等职。2001年回国后创立睿星基因技术有限公司，任总经理、董事长，并兼任国家人类基因组研究中心功能基因研究部主任和上海交通大学客座研究员等职，同时承担了多项国家”863”、自然科学基金、和科技攻关重大专项等课题组长，并荣获上海市政府银质奖章和多项荣誉和奖励。睿星基因于2005年与GNI公司合并上市，罗楹同时兼任GNI公司董事长、总经理。他曾在国际领先生物科学杂志发表了35篇科研文章，并应邀在国际药业杂志撰写多篇综述，介绍国内生物医药行业发展。公司的创业和发展，受到美国华尔街日报、英国金融时报、CNBC日经频道、及上海电视台等媒体多次报道。

Dr. Ying Luo joined PekingUnionMedicalCollege to study medicine in 1982 and earned his Ph.D. degree of Molecular Biology and Biochemistry at the University of Connecticut Health Center of the United States in 1986. His postdoctoral research was on HIV gene regulation at the University of California at San Francisco in 1992. From 1993 to 2000, he took various positions in biotech companies in the San Francisco Bay Area, including Aviron, Clontech, and Rigel. In 2001, he returned to China to join the ShanghaiNationalGenomeCenter as Direction of Functional Genomics. His main research interest is to study protein-protein interactions in yeast. At the meantime, he is also Founder and CEO of Shanghai Genomics, Inc. >From 2001, Dr. Luo has led three Chinese National “863” Hi-Tech Development Projects and multiple Shanghai local government research projects. In his career, he had co-authored more than 35 research publications in leading international journals of life sciences and wrote several review articles covering the changing trends of the Asian biotechnology industry. His venture experience in Shanghai was reported in the first column of the front page of the Wall Street Journal in 2003, London Financial Times, CNBC Nikkei, and Shanghai TV channels. He is frequently invited to give speeches worldwide. In 2007, he was awarded the Magnolia Silver Medal by Shanghai Municipal Government for his contribution to the economic development and modernization of Shanghai.

Birger Sørensen CEO, Bionor Immuno AS, Norway

Co-Founder of Bionor Immuno AS (vaccine development), Co-Founder of Bionor AS (diagnostic test kit development), Co-Founder of A/S Telelab (clinical pathology laboratory for the county of Telemark) - a trade sale exit was completed in 2007, Co-Founder and chairman of Norsk Miljøkraft AS – owner of large Norwegian wind power parks. One of the parks (40 MW) was sold in 2002. Former chairman of the Norwegian Bioindustry Association. Other work experience; Managing Director of Bionor since 1985. Physical chemist (M.Sc./Cand real), software development and statistical modeling of biological properties, development of immunoassays (bacterial as well as virus), analysis of proteins and design of peptide

Prof Douglas J. Cork, PhD Prof of Biology, IIT, Chicago & MHRP/HJF, Walter Reed Army Institute of Research

Expertise - Computational Bioinformatics, Bench driven work on Salmonella, E.coli, Chlorobium, SRB’s and Bacillus, Pseudomonas Education - B.S. Chemistry, University of Arizona & Ph.D. Agricultural Chemistry, University of Arizona Research & Major Accomplishments The W-curve is a graphical comparison technique for analyzing DNA or RNA genomes. It uses a 3-dimensional abstraction of the genomes. The goal of our research is to use this geometric approach to permit a wider range of scoring techniques that may prove more effective for HIV-1 clinical use and vaccine development than SNP or gap scoring. At this point we have a working comparison tool but need to validate it for clinical use. This includes adapting the existing methods for quickly locating sequences on the genome, building a library of Env & Pol features for comparison, and validating the matching process against known clinical outcomes. At least part of this will involve tuning the comparison algorithm to produce values appropriate for creating "clinical" (vs. evolutionary) trees and clades. The final outcome of our effort should be tools for building a library of known features, comparing sequences to them, and producing clinically useful results. So far, we have successfully developed heuristics for defining distances and gaps between similar W-curves of HIV-1 genomes. We would like to correlate changes in the W-curve of HIV-1 genomes with clinical changes seen in HIV-1 cohort trials.

Dr. Chei-Hsiang Chen Director, Biotechnology and Pharmaceutical Industries Program Office (BPIPO)

Dr. Chei-Hsiang Chen has held the position of Director, Biotechnology and Pharmaceutical Industries Program Office (BPIPO) since 2003. BPIPO was established to serve as the "one-stop service office" where biotech companies can seek assistance or contact to explore partnership and business opportunities in Taiwan. This office aggressively promotes collaboration with international strategic partners. With personal devotion and wide industrial experience, Dr. Chen has been playing a very important role for the promotion of Taiwan’s biotech industry Dr. Chen received his doctoral degree of Microbiology from the University of Texas at Austin in 1987, and joined Development Center for Biotechnology (DCB), Taiwan as a research fellow, Microbiology Division in 1988. DCB is a non-profit R&D Institute and was established in 1984. The main mission of DCB is to assist the development of Taiwan’s biotech industry through R&D, infrastructure-building and talent development programs. Dr. Chen held the positions of Program Director and Senior Research Fellow from 1990 to 2000 and had extensive research experience in the agricultural and environmental biotech areas. He was transferred to Industry Promotion Division and promoted as Managing Director in 2000 and was responsible for the business development and international cooperation for the Center. He was listed in the Marquis Who’s Who in the World 2002 and in Science and Engineering 2003-2004, respectively.

Dr. Jaap Goudsmit CSO, Crucell, The Netherlands

Jaap Goudsmit received his MD degree from the Faculty of Medicine of the University of Amsterdam in 1978 and his PhD degree from the same university in 1982. In 1978 he was awarded a Fogarty fellowship and in 1982 a Fogarty visiting scientist award to postdoctoral research at the National Institutes of Health in Bethesda, Maryland USA. In 1983 Jaap Goudsmit was board certified in the Netherlands as a Medical Microbiologist. From 1996 till 2002 Jaap Goudsmit has been head of the Department of Human Retrovirology at the Academic Medical Center (AMC) of the University of Amsterdam (UvA). >From 1989 till 2002 Jaap Goudsmit was affiliated to the AMC as full Professor of virology. From 1999 till 2002 Jaap Goudsmit was chairman of the AMC Research Institute for Infectious Diseases and chairman of the AMC Institute for Science Education. Since 1984 Jaap Goudsmit is one of the principal investigators of the Amsterdam Cohort Studies of homosexual men and IV drug users, focusing on the natural history and the pathogenesis of AIDS. From 1994-2002 Jaap Goudsmit chaired the Scientific Advisory Committee of the International AIDS Vaccine Initiative (IAVI), the premier non-governmental driving force for a global HIV vaccine. >From 2000 till 2004 he has been a member of the board. From 1993-1996 Jaap Goudsmit was visiting professor at the Aaron Diamond AIDS Research Center of New York University, USA. From 1993 till 2002 Jaap Goudsmit has been project leader and (co)chair of Eurovac, the EU AIDS vaccine effort to bring promising vaccine concepts to phase I human testing. In 2002 Jaap Goudsmit has been affiliated to AMC through his appointment of Professor of poverty-related communicable diseases. As per March 2002 Jaap Goudsmit is affiliated with Crucell, a leading biotechnology company in Leiden. He started as Senior Vice President Vaccine Research. In July 2002 he accepted the position of Chief Medical Officer and became a member of the Executive Committee as Executive Vice President Vaccine Research and Development. Since September 2002 he holds the position of Chief Scientific Officer and Head Research and Development. In January 2004 he became a member of Crucell's Management Board.

Dr. Rajendra Mehta Assistant VP and Head of the Cancer Biology, Head of Drug Discovery Divisions at IIT Research Institute

Rajendra G. Mehta, Ph.D, is Assistant Vice-President and Head of the Cancer Biology as well as the Drug Discovery Divisions at IIT Research Institute. He is also Professor of Biology at the Illinois Institute of Technology (IIT) and holds a joint appointment as Professor of Surgical Oncology at the University of Illinois Medical School, Chicago, IL. Dr. Mehta’s primary research activities are in the areas of efficacy and molecular mechanism(s) of action of cancer preventive agents, as well as preclinical development of chemopreventive agents derived form natural products. He has served as Principal Investigator or Project Leader on numerous research grants, contracts, program projects, and training grants funded by the National Cancer Institute (NCI). He was instrumental for development of Fenretinide (4HPR, a synthetic retinoid), resveratrol (from red wine) deguelin (from a plant) non-toxic vitamin D analog. His expertise is to take a new cancer preventive agent from bench to clinic. This includes discovery, establishing efficacy, understanding molecular mechanism(s) of their action leading to clinical trials. In addition, he is constantly involved in developing strategies for cancer prevention. Dr. Mehta has published more than 165 peer-reviewed research papers and reviews. He has given presentations as an invited speaker at numerous national and international conferences and at academic institution. He also holds two US patents as a co-inventor. Dr. Mehta has served on several grant review panels for NCI, DOD, ACS, VA, and the USDA.

Dr. Grace Wong PhD, CEO, ActoKine Therapeutics

Grace has spent her entire career on biologics, specifically on cytokines, at Genentech, Millennium, AstraZeneca and Serono. Her PhD project was on biologics at The Walter and Eliza Hall Institute of Medical Research, Australia. Her post-doc projects were also on biologics with Dr. David Goeddel at Genentech. She continued working on biologics in a variety of diseases at Genentech, Millennium, AstraZeneca and Serono. Grace successfully shepherded basic research discoveries to product development at Genentech in 1993 and was appointed Head of Apoptosis Research at Millennium in 1996 for discovery of cytokine inducible drug resistance genes using functional genomics. Grace joined AstraZeneca as Section Head of Molecular Genetics for discovery of cytokine inducible genes in Alzheimer’s disease. At Serono, Grace was Director of Cytokine Genomics for discovery of novel cytokines in Women’s diseases. Her work with biologics have made her valuable to biotech and pharma, receiving also job offers from Glaxo, Biogen, Human Genome Sciences and Cell Therapeutics, in addition to the positions she was able to accept. Grace has been invited to present at 160 international conferences including the Nobel Symposium in Sweden in 1994. Grace received 13 scholarships and 5 Recognition Awards from Genentech. She published 89 papers and 27 patents (11 issued). Some of her publications (3 Nature, 1 Science, 3 Cell, 5 PNAS and 7 J. Immunol) have received 300-1000 citations. Grace founded ActoKine Therapeutics to discover new biologics for radioprotection and prevention of a board spectrum of viral infection (www.actokine.com). Grace also founded Student Vision (www.studentvision.org) and Nobel-Pauling (www.pauling.us) to inspire and help students of all ages in biotechnology.